Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
|Articles|September 2, 2016
- Pharmaceutical Technology-09-02-2016
- Volume 40
- Issue 9
Pharmaceutical Technology, September 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Technology September 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 10 years ago
The Internet of Things for Pharmaceutical Manufacturingabout 10 years ago
How to Get the Most Out of Facility Renovationsabout 10 years ago
Root Cause Analysis–Finding the Root of the Problemabout 10 years ago
New Directions in Modular Manufacturingabout 10 years ago
Efforts Accelerate to Streamline Postapproval Change Processabout 10 years ago
Common Deficiencies in ANDAs for Dermatologic Drug Productsabout 10 years ago
Maintaining Hygienic Diaphragm Valvesabout 10 years ago
Tumble Blenders Include Improved Safety Featuresabout 10 years ago
Analyzer Automates Cell-Culture Chemistry Analysisabout 10 years ago
Data Logger Provides Ultra-Low Temperature ReadingsAdvertisement
Related to this article
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
The new initiative aims to apply traceable AI and science to expand care worldwide by translating discovery into tools that accelerate drug development.
Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific, provides an update on the progress of AI and machine learning used in drug delivery.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5